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Abstract
Objectives: The frequency of common oncogenic mutations and TP53 was determined in Asian oral squamous cell
carcinoma (OSCC).
Materials and Methods: The OncoCarta™ panel v1.0 assay was used to characterize oncogenic mutations. In
addition, exons 4-11 of the TP53 gene were sequenced. Statistical analyses were conducted to identify associations
between mutations and selected clinico-pathological characteristics and risk habits.
Results: Oncogenic mutations were detected in PIK3CA (5.7%) and HRAS (2.4%). Mutations in TP53 were
observed in 27.7% (31/112) of the OSCC specimens. Oncogenic mutations were found more frequently in non-
smokers (p = 0.049) and TP53 truncating mutations were more common in patients with no risk habits (p = 0.019).
Patients with mutations had worse overall survival compared to those with absence of mutations; and patients who
harbored DNA binding domain (DBD) and L2/L3/LSH mutations showed a worse survival probability compared to
those patients with wild type TP53. The majority of the oncogenic and TP53 mutations were G:C > A:T and A:T >
G:C base transitions, regardless of the different risk habits.
Conclusion: Hotspot oncogenic mutations which are frequently present in common solid tumors are exceedingly
rare in OSCC. Despite differences in risk habit exposure, the mutation frequency of PIK3CA and HRAS in Asian
OSCC were similar to that reported in OSCC among Caucasians, whereas TP53 mutations rates were significantly
lower. The lack of actionable hotspot mutations argue strongly for the need to comprehensively characterize gene
mutations associated with OSCC for the development of new diagnostic and therapeutic tools.
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Introduction
Oral squamous cell carcinoma (OSCC), a subset of head
and neck squamous cell carcinoma (HNSCC), is one of the
most common malignancies with more than 400,000 of new
cases diagnosed annually worldwide [1]. Particularly in South
East Asia, the disease is reaching epidemic proportions with
age-standardized rates (ASR) of 6.7 compared to 4.3 and 4.0
in Europe and America respectively [2]. The disease has
significant physical and psychological morbidity and a survival
rate of approximately 50% over 5 years, a figure that reflects
the stage of the tumour at presentation and the development of
loco-regional recurrences, distant metastases and second
primary tumours. Survival rates have not improved for decades
and taken together, the findings argue strongly for the need to
develop new therapeutic strategies.
Cancer occurs due to the progressive accumulation of
abnormalities in cellular DNA which, in turn, provide a selective
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growth advantage to cancer cells and facilitate metastatic
dissemination [3]. Dysregulation of certain signaling pathways,
together with chromosomal abnormalities, have been identified
in HNSCC [4] and more recently, TP53, CDKN2A, PIK3CA,
PTEN and HRAS, together with FBXW7, NOTCH1, IRF6 and
TP63, have been shown to play fundamental roles in the
pathogenesis of HNSCC [5-7]. Further, the nature of gene
mutation is thought to reflect the exposure to specific risk
factors, with G > T transversions at non-CpG sites being
characteristic of tobacco exposure [6,8]. However, these and
other studies [5,9,10] have been undertaken using tissue
specimens and cell lines from Caucasian populations where
smoking and excessive alcohol consumption are primary risk
factors. By contrast, very little is known about the spectrum of
gene mutations in OSCC of Asian origin where the disease is
most prevalent [1] and where the practice of betel quid
chewing, with or without smoking has been demonstrated to be
associated with the increase risk to oral cancer in about 50% of
the patients [11-13].
Mutations in genes that play fundamental roles in driving
cancer development have defined treatment protocols in a
diverse group of tumor types [14,15], but information regarding
oral squamous cell carcinoma is limited. In the present study,
we used high-throughput mutational profiling to determine the
prevalence of mutations at 238 sites across 19 oncogenes in
Asian OSCC as well as TP53 in 107 tissues and 16 cell lines.
We demonstrate lower levels of TP53 mutations but similar
mutational frequencies in HRAS and PIK3CA in Asian OSCC
compared to Caucasian OSCC. Most notably, we show that
mutations in the 19 oncogenes are exceedingly low compared
to other solid cancers including lung cancer where the
etiological factors are similar to that of OSCC. The findings
suggest that mutations other than those commonly seen in
solid cancers may play an important role in driving OSCC and
argue strongly for further comprehensive analysis of gene
mutations in this tumor type.
Materials and Methods
Ethics Statement
All of the clinical samples were obtained from patients with
written informed consent, and this study was approved by the
Institutional Review Board of the Faculty of Dentistry,
University of Malaya (Medical Ethics Number: DF
OS1002/0008/L).
The 16 cell lines that were used in this study were
established in our laboratory and have been described
previously [16]. These were established from tissues that were
collected with written informed consent and were approved by
the Institutional Review Board of the Faculty of Dentistry,
University of Malaya (Medical Ethics Number: DP
OP0306/0018/L).
Clinical samples and cell lines
One hundred and thirty genomic DNA (gDNA) samples from
107 fresh frozen OSCC tissues, 16 oral squamous cell
carcinoma (OSCC) cell lines and 7 control cell lines positive for
specific mutations were included in this study. gDNA from
OSCC tissues that had a minimum of 70% tumor coverage and
the data associated with these specimens were obtained from
the Malaysian Oral Cancer Database & Tissue Bank System
(MOCDTBS) [17]. Information pertaining to the tissue
specimens is shown in Table 1. Sixteen OSCC cell lines (Table
S1 in File S1) were established from primary explant cultures in
our laboratory, as described previously [16]. With the exception
of ORL-156, all of the cell lines have been authenticated to
tissues and/or blood samples. ORL-156 has a suspicious
identity with a 60% match to the original tumor tissue. gDNA
from seven cell lines which contained mutations in specific
genes were kind gifts from Dr. Ramsi Haddad, Laboratory of
Translational Oncogenomics, Karmanos Cancer Institute,
Wayne State University, USA (Table S2 in File S1). Five of
these lines originated from breast carcinomas [18,19], one was
from an ovarian cancer [20] and another was from an ovarian
cancer mouse xenograft. All gDNA extraction was performed
using the QIAamp DNA mini kit (Qiagen, Germany), according
to manufacturer’s recommendation and the quantity and quality
of gDNA was determined using the NanoDrop ND1000
Spectrophotometer and gel agarose electrophoresis.
High-throughput somatic mutation detection and
analysis
The OncoCarta™ Panel v1.0 assay (Sequenom, San Diego,
CA, USA) was used for the detection of somatic mutations
because it is a rapid and cost effective method of identifying
key cancer driving mutations also known as “actionable
mutations” across a large number of samples. Two key
advantages of using the Sequenom platform, which detects
mutations based on the mass of the sequence, are 1) it has the
ability to simultaneously profile multiple mutations in several
genes in an large number of samples through multiplexing and
2) it can provide a 3-fold increase in mutation detection limit (as
low as 5-10% of the mutant allele) compared to sequencing. In
order to analyze these hotspot mutations, multiplex reactions
were prepared, spotted on the SpectroChipII using the
MassARRAY® Nanodispenser, resolved by MALDI-TOF on the
Compact Mass Spectrometer (Sequenom, San Diego, CA,
USA) and analyzed using the MassARRAY® Typer Analyzer
software 4.0.22 where an OncoMutation™ report to indicate
mutant specimens by comparing the ratios of the wild type
allele peak to those of suspected mutant allele peak is
automatically generated, as described by others [21,22]. The
hotspot mutations that were included in this assay are
tabulated in Table S3 in File S1.
Polymerase Chain Reaction (PCR) and direct DNA
sequencing
All of the mutations that were detected by the OncoCarta™
Panel v1.0 assay (Sequenom, San Diego, CA, USA) were
validated by direct sequencing. The PIK3CA, BRAF, EGFR,
HRAS, KRAS, NRAS and MET oncogenes were also
sequenced in the 16 oral cancer lines to ensure concordance
between the OncoCarta™ Panel v1.0 assay and direct
sequencing. The chosen genes were selected for their high
mutation frequency in HNSCC according to the Catalogue of
Somatic Mutations in Cancer (COSMIC) v60 information
Mutational Profiling in Oral Cancer
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database (http://www.sanger.ac.uk/genetics/CGP/cosmic/) [23].
In all, 13.0% (16/123) of the total samples covering more than
a third (7/19; 36.8%) of the total genes on the OncoCarta™
Panel v1.0 were sequenced for concordance between the two
mutation detection methods. PCR and sequencing were
performed as described previously [16,24,25]. The primers are
tabulated in Table S4 in File S1. The generated sequences
were compared with the reference sequences of the respective
genes using the Basic Local Alignment Search Tool [26]
(BLAST, NCBI, Maryland, USA; Table S4 in File S1). The
frequency and spectrum of mutations were compared to those
reported in COSMIC.
Table 1. Demographics and clinico-pathological
characteristics of patients included in the study.
Variable  n=107 %
Gender Male  43 40.2
 Female  63 58.9
 Information unavailable  1 0.9
Age Mean 58 -- --
 Range 58 -- --
Risk Habits Exclusively smokers  12 11.2
 Exclusively betel quid chewers  35 32.7
 Exclusively alcohol drinkers  3 2.8
 Two Habits    
 Chewing + Smoking  4 3.7
 Chewing + Drinking  7 6.5
 Smoking + Drinking  12 11.2
 All 3 Habits  7 6.5
 None  23 21.5
 Information unavailable  4 3.7
Tumor Site Buccal  41 38.3
 Tongue  34 31.8
 Gum  17 15.9
 FOM & palate  6 5.6
 Information unavailable  9 8.4
Tumor Size Tis, T1 & T2  40 37.3
 T3 & T4  51 47.7
 Information unavailable  16 15.0
Lymph Node Metastasis Negative  47 43.9
 Positive  44 41.1
 Information unavailable  16 15.0
TNM Stage Early (I & II)  31 29.0
 Late (III & IV)  60 56.0
 Information unavailable  16 15.0
Tumor Differentiation Well  42 39.3
 Moderate/poor  48 44.9
 Information unavailable  17 15.9
Overall survival Range (months) 1-91 -- --
 Median 18 -- --
 Mean 22.8 -- --
doi: 10.1371/journal.pone.0080229.t001
Detection of TP53 somatic mutations in OSCC
The mutational status of TP53 was determined in 112 OSCC
samples that were used in the OncoCarta™ Panel v1.0 assay.
The positive control cell lines with oncogenic mutations (n=7)
and 11 OSCC samples with insufficient DNA were excluded.
Mutation detection was conducted by direct sequencing of
exon 4 to exon 11 where more than 85% of TP53 mutations
have been reported [27]. The procedures of PCR, purification,
sequencing and analysis have been described previously [16].
The primer sequences for TP53 are tabulated in Table S4 in
File S1. The TP53 mutations found in this study were
compared to those reported in the IARC version R15 (http://
www-p53.iarc.fr/) [28]. Mutations were classified into five
groups: DNA binding domain (DBD), L2/L3/LSH hotspot,
disruptive and truncating, and based on functional
consequences, as described by others [29-31].
Statistical Analysis
All statistical analyses were performed using the SPSS
software (SPSS for Windows, version 16.0 (Chicago, IL) to
determine statistical associations of mutations with risk habits
and pathological parameters. Survival probability differences
were compared by the log-rank test using Kaplan-Meier
survival analysis. A p-value of <0.05 was considered
statistically significant.
Results
Mutations in OSCC
Of the 123 specimens (107 OSCC tissues, 16 OSCC cell
lines), 38 (30.9%) had at least one mutation taking into account
both oncogenic mutations and TP53 mutations (Table S5 in
File S1). Ten oncogenic mutations were detected in eight
specimens (7 OSCC tissues and 1 OSCC cell line; 6.5%) and
these mutations were found in the PIK3CA and HRAS genes.
Two of the OSCC tissues had mutations in both genes
(06-0005-10 and 01-002-10). The majority of oncogenic
mutations were detected via the OncoCarta™ Panel v1.0 assay
whilst others were detected via direct sequencing, as described
in detail below. Of the oncogenic mutations that were identified,
all but one was base transitions (Table 2). Notably, no
mutations were detected in the remaining 17 oncogenes.
Mutations in the PIK3CA gene were detected in 7/123 (5.7%)
specimens. Mutations at H1047R, E545K, Q546R, E542K, and
M1043I were found in six OSCC tissues and one cell line, and
the mutated allele frequency ranged from 17-50% (Table 2).
The Q546R mutation, not present in the OncoCarta™ Panel
v1.0 assay, was detected in sample ORL150T by direct
sequencing. HRAS was the only other gene that was mutated
and mutations were detected in 3/123 (2.4%) of specimens.
Mutations at G12S and G12D were detected in three OSCC
tissues, with mutation allele frequencies of 23-82%; no
mutations were detected in the cell lines (Table 2). We used
seven cell lines from various tissue types as positive controls in
the OncoCarta™ Panel v1.0 assay and all of the mutations that
were harbored in these cell lines have been documented in
Table S2 in File S1. The concordance between the
Mutational Profiling in Oral Cancer
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OncoCarta™ Panel v1.0 assay and direct sequencing was
99.9% (data not shown).
Thirty three TP53 mutations were found in 31/112 specimens
(27.7%). The cell lines ORL48T and ORL195T had two TP53
mutations respectively (Table 3). The majority of the mutations
were base transitions (60.6%) with G:C to A:T being by far the
most common alteration (48.5%; Table 3). Most of the
mutations occurred within the DBD (81.8%), 63.6% occurred in
L2/L3/LSH domain, 24.2% were hotspot mutations and 48.5%
and 27.3% were disruptive and truncating mutations,
respectively. Notably, the missense mutation M237K and
designated hotspot mutations R175H, R248Q and R273C were
found in more than one OSCC specimen (Table 3). One of the
patients who had mutations in both PIK3CA and HRAS, also
carried a TP53mutation (06-0005-10; Table 3). All except 3
samples (2.7%; ORL-115, 06-0027-05 and 11-0010-10) were
negative for HPV. Two of the 3 specimens which were positive
for HPV had TP53 mutations (data not shown).
Association of mutations with risk habits and clinico-
pathological characteristics
The presence of any mutation (oncogenic or TP53) was not
significantly associated with exposure to risk habits (Table S6
in File S1). Notably, patients with any mutation had a worse
survival compared to those with a complete absence of
mutations (Figure 1a). However, the presence of any mutation
was not an independent factor for poor survival (Table 4).
Seven out of eight OSCCs which harbored oncogenic
mutations were from patients exposed to risk habits but
interestingly oncogenic mutations were identified in patients
who did not smoke (8/8; p = 0.049; Table 5).
The mutational frequencies of TP53 in patients with the
different risk habits were similar (Table 6). Regardless of the
nature of the risk habits, base transitions were the most
common mutations (Table S7 in File S1). Truncating mutations
were significantly enriched in OSCC patients with no risk habits
(23.8%) compared to 4.6% in patients with at least one risk
factor (p =0.019). All types of TP53 mutations were enriched
significantly in OSCC cell lines compared to OSCC tissues
(Table 7). In addition, patients who harbored DBD and
L2/L3/LSH mutations showed a worse survival probability
compared to patients who had wild type TP53 (Figure 1b, 1c,
1d) but the Cox-Regression analysis showed that TP53
mutations were not a significant independent factor in
modulating survival (Table 4).
Discussion
The comprehensive profiling of cancer mutations in tumor
samples has led to the detection of key perturbations that
promote tumorigenesis in many types of cancers. Further, with
the advent of next generation sequencing, the genomes of
many types of cancers can be comprehensively characterized
[32]. Such technology, however, is limited by the cost of
characterizing large numbers of samples. For example, next
generation sequencing data on OSCC are still limited [5-7,33]
and comprehensive mutational information on OSCC amongst
Asians, where the incidence is most prevalent is still
unavailable. High-throughput analysis of key cancer driving
mutations using mass-spectrometry remains a cost effective
and efficient way of analyzing multiple mutations across a large
number of samples, particularly when these are known and
could influence clinical management of patients [22].
In this study, we examined the spectrum of oncogenic
mutations across ABL1, AKT1, AKT2, BRAF, CDK4, EGFR,
ERBB2, FGFR1, FGFR3, FLT3, HRAS, JAK2, KIT, KRAS,
MET, NRAS, PDGFRA, PIK3CA and RET in a broad spectrum
of tissues and cell lines derived from Asian OSCC. The
mutation sites that were included in the OncoCarta™ Panel v1.0
assay are those that are frequently seen in many different
types of solid tumors and are clinically actionable. Information
concerning 12 of the 19 oncogenes investigated by the
OncoCarta™ Panel v1.0 assay is either limited or absent in
COSMIC for OSCC. In this study, PIK3CA and HRAS were the
only two oncogenes mutated. Notably, only 6.5% of OSCC
patients harbored at least one PIK3CA and HRAS mutation,
whereas, these oncogenic mutations occur in 30-70% of solid
tumours, including colorectal, ovarian, endometrial, lung,
melanoma and breast cancer (Table S8 in File S1) [22,34].
Table 2. Oncogenic mutations in OSCC.
Gene Mutation Mutation type Sample Mutant allele frequency Site pTb pNb pMb Stageb Habit
HRAS G12S G:C > A:T 03-0004-04a n/a information unavailable Information unavailable BQ chewing
 G12D G:C > A:T 01-0002-10 23% Buccal 4 0 0 IV BQ chewing
 G12D G:C > A:T 06-0005-10 82% Buccal 2 0 0 II BQ chewing & Alcohol Drinking
PIK3CA H1047R A:T > G:C 01-0016-07 17% Buccal 1 0 0 I BQ chewing
 H1047R A:T > G:C 04-0005-04 45% Buccal 4 0 0 IV BQ chewing & Alcohol Drinking
 E545K G:C > A:T 01-0025-07 50% Tongue 3 0 1 IV None
 E545K G:C > A:T 01-0002-10 30% Buccal 4 0 0 IV BQ chewing
 E542K G:C > A:T 01-0011-10 24% Tongue 4 1 0 IV BQ chewing
 Q546R A:T > G:C 150Ta n/a Tongue 1 0 X I Alcohol Drinking
 M1043I G:C > T:A 06-0005-10 32% Buccal 2 0 0 II BQ chewing & Alcohol Drinking
a. Mutations were detected only through direct DNA sequencing
b. Pathological characteristic
doi: 10.1371/journal.pone.0080229.t002
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Further, mutations in 5 of 19 genes identified by the
OncoCarta™ Panel v1.0 assay are typically seen in many of
these cancers [22,34]. With respect to lung cancer, for
example, which shares similar risk factors to OSCC, mutations
of PIK3CA, HRAS, NRAS, KRAS, BRAF, EGFR, ERBB2,
PDFGRA and RET are seen in some 30% of patients [34].
Whole exome sequencing reported by Stransky et al. (2011)
and Agrawal et al. (2011) indeed have provided us with
comprehensive information on the mutation spectrum in
HNSCC but their work has been confined to Caucasian
samples. Interestingly, the results of the present study are
similar to those reported for OSCC in patients of Caucasian
origin with low mutation frequencies in ERBB2 (1/32 patients),
FLT3 (1/38 patients) and EGFR (1/38 patients) [5,6]. More
recently, a similar comprehensive integrative genetic analysis
reported by Pickering et al. (2013) also revealed that
aberrations in OSCC are commonly confined to mitogenic
signaling pathway which mostly involves genes such as PI3K
and RAS [7]. The results suggest that mutations within this
spectrum of oncogenes appear not to be a characteristic of
OSCC and, most probably, are unrelated to risk factors such as
tobacco, alcohol and betel quid chewing that are historically
associated with OSCC.
Deregulation of HRAS is known to activate two major
signaling pathways, namely, PI3K/AKT and MAPK [35,36]. In
this study, only some 3% of samples contained HRAS
mutations, findings that were surprising in view of the fact that
studies in India have reported higher HRAS mutation
frequencies [37-39] whereas those relating to Caucasian
patients with OSCC range from 4-8% [5,6,40,41]. Historically,
the high prevalence of HRAS mutations in the Indian
subcontinent has been attributed to betel quid chewing [37] but
Figure 1.  The presence of mutations in association with overall patient survival.  Log Rank (Mantel-Cox) test showing that
patients who harbor (a) overall TP53 and oncogenic mutations, (b) overall TP53 mutations, (c) L2/L3/LSH TP53 mutations and (d)
DBD TP53 mutations have a worse overall survival compared to wild type patients.
doi: 10.1371/journal.pone.0080229.g001
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the patients used in the present study were also betel quid
chewers suggesting that the low mutational frequency of HRAS
in this study was due to factors other than risk factor exposure.
Other up- or down-stream proteins within the RAS pathway
such as activation or over-expression of EGFR [42], and/or loss
Table 4. Multivariate analysis of different types of mutations
with overall survival.
Multivariate Analysis p value risk ratio (95% CI)
(A) Oncogenic + TP53 mutation (Wild type vs
mutation) 0.144 1.551 (0.861 - 2.794)
Age group (≤ 58 vs > 58) 0.030 1.873 (1.062 - 3.301)
Lymph Nodes Metastasis (Positive vs Negative) <0.001 4.849 (2.102 - 11.183)
Staging (Early vs Late) 0.719 0.85 (0.350 - 2.060)
(B) Overall TP53 mutation (Wild type vs
mutation) 0.319 1.416 (0.715 - 2.803)
Age group (≤ 58 vs > 58) 0.037 1.906 (1.039 - 3.497)
Lymph Nodes Metastasis (Positive vs Negative) <0.001 5.748 (2.238 - 14.76)
Staging (Early vs Late) 0.444 0.687 (0.262 -1.798)
(C) L2/L3/LSH mutation (Wild type vs
mutation) 0.128 1.801 (0.844- 3.841)
Age group (≤ 58 vs > 58) 0.026 2.073 (1.093 - 3.930)
Lymph Nodes Metastasis (Positive vs Negative) 0.001 5.202 (2.053 - 13.183)
Staging (Early vs Late) 0.476 0.711 (0.279 - 1.815)
(D) DNA Binding Domain mutation (Wild type
vs mutation) 0.294 1.442 (0.728 - 2.859)
Age group (≤ 58 vs > 58) 0.041 1.883 (1.026 - 3.454)
Lymph Nodes Metastasis (Positive vs Negative) <0.001 5.628 (2.195 - 14.435)
Staging (Early vs Late) 0.429 0.68 (0.261 -1.769)
doi: 10.1371/journal.pone.0080229.t004
of PTEN [43] can result in the activation of the RAS signaling
pathway, and may be a reason for the lack of RAS mutations in
the present study.
PIK3CA mutations occur frequently in many cancers
including colorectal, breast, brain, gastric, ovarian and lung and
75% of these occur in exons 9 and 20 [34,44]. Hotspot
mutations at these sites (E545K, E542K and H1047R) increase
kinase activity and induce transformation, tumour cell
proliferation, invasion and metastasis [45-47] resulting in over
activated PI3K pathway as shown in in vitro and in vivo models
[48,49]. Oncogenic activation of this pathway is one of the most
commonly de-regulated pathway implicated in HNSCC [50]. In
the present study, hotspot PIK3CA mutations were found in
5.7% of OSCC specimens, findings that confirm previous
observations in both Asian [51,52] and Caucasian populations
[5,6,9].
Importantly, the fact that oncogenic mutations occur in a
small subset of OSCC patients suggests that they may benefit
from targeted therapy as opposed to the conventional
treatment modalities. While only a small percentage of patients
may have such mutations, this translates to significant patient
numbers when the global incidence of the disease is
considered. PIK3CA mutations, for example, have been
demonstrated to modulate response to mTOR- and EGFR-
targeted therapy [53-55]. New generation of drugs targeting
PI3K are currently being tested clinically (NCT01690871,
NCT01219699, and NCT01501604) on patients with and
without PIK3CA mutations, and results from these trials should
provide further information on the role of these mutations in
modulating drug response. Although the inhibition of RAS
genes was relatively unsuccessful in previous studies, the
activation of HRAS in a subset of HNSCC suggests that this
Table 5. Oncogenic mutations in association with risk habits and pathological characteristics.
Risk Habits/Pathological Characteristic Patients (n) Wildtype oncogenic mutations ap-value odds ratio 95% confidence
Overall Habit Any habit 94 86 (92.5%) 7 (7.5%) 0.682 2.01 (0.24-17.13)
 No habit 26 26 (96.3%) 1 (3.7%)    
Smoking Ever smokersb 43 42 (100%) 0 (0%) 0.049 - -
 non-smokers 77 70 (89.7%) 8 (10.3%)    
Btel Quid chewing Ever chewersb 60 54 (90%) 6 (10%) 0.272 3.22 (0.62-16.66)
 non-chewers 60 58 (96.7%) 2 (3.3%)    
Alcohol drinking Ever drinkersb 35 32 (91.4%) 3 (8.6%) 0.690 1.50 (0.34-6.65)
 non-drinkers 85 80 (94.1%) 5 (5.9%)    
Lymph Node Metastasis Negative 54 46 (88.5%) 6 (11.5%) 0.056   
 Positive 54 54 (98.2%) 1 (1.9%)    
TNM stage Early (0, I, II) 36 32 (91.4%) 3 (8.6%) 0.679   
 Late (III & IV) 72 69 (94.5%) 4 (5.5%)    
aData included OSCC tissues and cell lines and analyzed by Pearson's Chi-Square Test and Fisher Exact Test
bPatients who ever smoke, chew, and drink may have more than one risk habit
Odds Ratio was not computed due to zero cell size
doi: 10.1371/journal.pone.0080229.t005
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Table 6. TP53 mutations in association with risk habits and pathological characteristics.
Risk Habits/Pathological
Characteristic
Patients
(n) Wild Type
overall TP53
mutations p-value
odds
ratio
95% confidence
intervals
Patients
(n) Wild Type
DBD
mutations p-value
odds
ratio
95%
confidence
intervals
Overall
Habit Any habit 86 62 (72.1%) 24 (27.9%) 0.605 0.774 0.293 2.044 84
62
(73.8%) 22 (26.2%) 0.823 1.135 0.372 3.465
 No habit 24 16 (66.7%) 8 (33.3%)     21 16(76.2%) 5 (23.8%)     
Smoking Eversmokers 40 29 (72.5%) 11 (27.5%) 0.781 0.885 0.374 2.096 39
29
(74.4%) 10 (25.6%) 0.989 0.994 0.402 2.460
 non-smokers 70 49 (70.0%) 21 (30.0%)     66
49
(74.2%) 17 (25.8%)     
Betel Quid
Chewing
Ever
chewers 55 39 (70.9%) 16 (29.1%) 1.000 1.000 0.439 2.277 54
39
(72.2%) 15 (27.8%) 0.619 1.250 0.519 3.012
 non-chewers 55 39 (70.9%) 16 (29.1%)     51
39
(76.5%) 12 (23.5%)     
Alcohol
drinking
Ever
drinkers 34 22(64.7%) 12 (35.3%) 0.338 1.527 0.640 3.642 32
22
(68.8%) 10 (31.2%) 0.390 1.497 0.594 3.771
 non-drinkers 76 56 (73.7%) 20 (26.3%)     73
56
(76.7%) 17 (23.3%)     
Lymph
Node
Metastasis
Negative 46 35 (76.1%) 11 (23.9%) 0.139    46 35(76.1%) 11 (23.9%) 0.427    
 Positive 53 33 (62.3%) 20 (37.7%)     48 33(68.8%) 15 (31.2%)     
TNM stage Early (I, II) 31 20 (64.5%) 11 (35.5%) 0.617    31 20(64.5%) 11 (35.5%) 0.288    
 Late (III &IV) 69 48 (69.6%) 21 (30.4%)     64
48
(75.0%) 16 (25.0%)     
Risk Habits/
Pathological
Characteristic
Patients
(n) Wild Type
Hotspot
mutations
p-
value
odds
ratio
95%
confidence
intervals
Patients
(n)
Wild
Type
DBD
mutations
p-
value
odds
ratio
95%
confidence
intervals
Overall
Habit Any habit 68 62 (91.2%) 6(8.8%) 0.671 0.774 0.143 4.204 72
62
(86.1%) 3 (4.6%) 0.316 0.516 0.155 1.724
 No habit 18 16 (88.9%) 2 (11.1%)     21 16(76.2%) 5 (23.8%)     
Smoking Eversmokers 33 29 (87.9%) 4 (12.1%) 0.476 1.69 0.392 7.276 32
29
(90.6%) 3 (9.4%) 0.200 0.422 0.110 1.623
 non-smokers 53 49 (92.5%) 4 (7.5%)     61
49
(80.3%) 12 (19.7%)     
Betel Quid
Chewing
Ever
chewers 43 39 (90.7%) 4 (9.3%) 1.000 1.000 0.233 4.286 47
39
(83.0%) 8 (17.0%) 0.813 1.143 0.378 3.458
 non-chewers 43 39 (90.7%) 4 (9.3%)     46
39
(84.8%) 7 (15.2%)     
Alcohol
drinking
Ever
drinkers 24 22 (91.7%) 2 (8.3%) 1.000 0.848 0.159 4.528 26
22
(84.6%) 4 (15.4%) 1.000 0.926 0.266 3.218
 non-drinkers 62 56 (90.3%) 6 (9.7%)     67
56
(83.6%) 11 (16.4%)     
Lymph
Node
Metastasis
Negative 37 35 (94.6%) 2 (5.4%) 0.263    40 35(87.5%) 5 (12.5%) 0.203    
 Positive 39 33 (84.6%) 6 (15.4%)     43 33(76.7%) 10 (23.3%)     
TNM stage Early (I, II) 21 20 (95.2%) 1 (4.8%) 0.432    26 20(76.9%) 6 (23.1%) 0.540    
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could be an opportunity for the revival of drugs such as
farnesyltransferase inhibitors.
One sample in this study had both PIK3CA and HRAS
activating mutations implying the significant synergistic signals
of PI3K and RAS pathway critical for oral carcinogenesis may
converge to activate a single downstream target that would be
critical for tumorigenesis [56]. Interestingly, a recent in vitro
study has shown that cells containing coexistence PIK3CA and
RAS mutations were resistant to PI3K inhibitors [57] suggesting
that coexistence of these mutations may be a predictive
biomarker for resistance to PI3K inhibitors.
In the present study, TP53 mutations occurred in 27.7% of
OSCC specimens, which is very similar to that reported in the
Indian subcontinent [58,59]. It is very apparent that the TP53
mutational frequency of OSCC patients from Asia (17-21%)
[58,59] differs dramatically from those reported from the West
(53-80%) [5,6,29]. The lack of TP53 mutations in these
samples were not due to involvement of HPV as only 2.7% of
the samples were positive for HPV. Further, these specimens
Table 7. Comparison of TP53 mutations between OSCC
tissues and cell lines.
TP53 mutation type
OSCC tissue samples;
n=96
OSCC cell line
samples; n=16 p-value*
overall 21 (21.88%) 12 (75.0%) <0.001
DBD 20 ( 20.83%) 7 (43.75%) 0.017
L2/L3/LSH 15 (15.63%) 6 (37.5%) 0.016
hotspot 5 (5.21%) 3 (18.75%) 0.032
disruptive 8 (8.33%) 8 (50.0%) <0.001
truncating 3 (3.13%) 6 (37.5%) <0.001
*. Data were analyzed using Fisher Exact Test
doi: 10.1371/journal.pone.0080229.t007
Table 6 (continued).
Risk Habits/Pathological
Characteristic
Patients
(n) Wild Type
overall TP53
mutations p-value
odds
ratio
95% confidence
intervals
Patients
(n) Wild Type
DBD
mutations p-value
odds
ratio
95%
confidence
intervals
 Late (III &IV) 55 48 (87.3%) 7 (12.7%)     57
48
(84.2%) 9 (15.8%)     
Risk Habits/
Pathological
Characteristic
Patients
(n) Wild Type
L2/L3/LSH
mutations
p-
value
odds
ratio
95%
confidence
intervals
Patients
(n)
Wild
Type
Truncating
mutations
p-
value
odds
ratio
95%
confidence
intervals
Overall
Habit Any habit 79 62 (78.5%) 17 (21.5%) 1.000 1.097 0.324 3.715 65
62
(95.4%) 3 (4.6%) 0.019 0.155 0.033 0.717
 No habit 20 16 (80.0%) 4 (20.0%)     21 16(76.2%) 5 (23.8%)     
Smoking Eversmokers 36 29 (80.6%) 7 (19.4%) 0.745 0.845 0.306 2.336 30
29
(96.7%) 1 (3.3%) 0.252 0.241 0.028 2.062
 non-smokers 63 49 (77.8%) 14 (22.2%)     56
49
(87.5%) 7 (12.5%)     
Betel Quid
Chewing
Ever
chewers 52 39 (75.0%) 13 (25.0%) 0.332 1.625 0.606 4.357 41
39
(95.1%) 2 (4.9%) 0.270 0.333 0.063 1.754
 non-chewers 47 39 (83.0%) 8 (17.0%)     45
39
(86.7%) 6 (13.3%)     
Alcohol
drinking
Ever
drinkers 30 22 (73.3%) 8 (26.7%) 0.381 1.566 0.571 4.298 24
22
(91.7%) 2 (8.3%) 1.000 0.848 0.159 4.528
 non-drinkers 69 56 (81.2%) 13 (18.8%)     62
56
(90.3%) 6 (9.7%)     
Lymph
Node
Metastasis
Negative 44 35 (79.5%) 9 (20.5%) 0.490    37 35(94.6%) 2 (5.4%) 0.263    
 Positive 45 33 (73.3%) 12 (26.7%)     39 33(84.6%) 6 (15.4%)     
TNM stage Early (I, II) 29 20 (69.0%) 9 (31.0%) 0.251    22 20(90.9%) 2 (9.1%) 1.000    
 Late (III &IV) 60 48 (80.0%) 12 (20.0%)     54
48
(88.9%) 6 (11.1%)     
Data included OSCC tissues and cell lines and analyzed by Pearson's Chi-Square Test and Fisher Exact Test
doi: 10.1371/journal.pone.0080229.t006
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had TP53 mutations reiterating the fact that HPV and TP53
mutations are not mutually exclusive events in OSCC [60].
Although both TP53 mutation and lymph node metastasis are
associated with overall survival (Table 4), there was no
significant association between TP53 mutation and lymph node
metastasis (Table 6). The association between TP53 mutations
and survival in the univariate analysis may reflect other
functions of mutant TP53 that is independent of metastasis. For
example, mutant TP53 have been shown to interfere with
mechanisms that maintain genome integrity including DNA
damage response pathways resulting in genomic instability
which is a major driver of cancer development and a hallmark
of cancer [61,62]. After considering other prognostic factors in
the multivariate analysis, lymph node metastasis was the only
significant factor associated with poor survival indicating that
lymph node metastasis is a stronger driving factor in
comparison to TP53 mutations, in determining the probability of
poor overall survival. Interestingly, TP53 mutations were more
prevalent in cell lines compared to OSCC tissues suggesting
that they may confer an advantage during the establishment
and propagation of the keratinocyte cultures. The results are
consistent with previous observations where TP53 mutations
facilitate the establishment of human myeloid cell lines [63] and
enhance tumor implantation in vivo [64]. Interestingly, the
diversity of TP53 point mutations makes this gene informative
for the identification of tumor- and exposure-specific mutation
patterns [65]. In the present study, 60.6% of TP53 mutations
were base transitions with G:C to A:T being the most common
alteration (48.5%; Table S7 in File S1). Similarly, G:C to A:T
transitions have been reported as the most predominant TP53
mutation in OSCC in Taiwan where risk habits include the use
of betel quid and tobacco [66]. However, truncating mutations
in the present study were found more frequently in OSCC
patients with absence of risk habits suggesting that inactivation
of TP53 may be important in the pathogenesis of OSCC.
Notably, one OSCC patient in this study has three concurrent
mutations in PIK3CA, HRAS and TP53. The prognostic
significance of this remains unclear as this was only observed
in one particular patient.
In summary, we show low mutation frequencies in Asian
OSCC compared to a broad spectrum of solid tumours. We
demonstrate that HRAS and PIK3CA mutations in Asian OSCC
are uncommon but comparable to that seen in the West. TP53
mutations, however, are significantly less common in Asian
compared to Caucasian OSCC. The findings may reflect
tumour heterogeneity and the diversity of risk factors between
the West and India and South East Asia, but this requires
verification. In the present study, the presence of actionable
mutations within a few key genes may ultimately be important
in clinical management. However, the data also demonstrate
the urgent need for a comprehensive genetic analysis of Asian
OSCC where the disease is most prevalent and where risk
factors differ from those seen in the West.
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